Psychiatry Flashcards

1
Q

Dementia

A

What?
Chronic, progressive global cognitive impairment with retained consciousness

Prevalence:
Over 65s = 5%
65-69 age group= 1%
80-84 age group = 12 %
Over 95 age group = 30% 

Risk factors:

  • FH
  • African-carribean
  • Sedentary lifestyle
  • T2DM
  • Strokes/CVD
  • Metabolic syndrome
  • Smoking
  • Females

Presentation:
Alzheimers: Loss of episodic memory + forgetfulness –> Anxiety and social decline
Later Visuospatial difficulties (parietal lobe) and changes to personality (frontal lobe)
Vascular= Stepwise deterioration, mainly speech and language decline
DLB= At first Lilliputian hallucination and fluctuating consciousness. Followed by motor symptoms of Parkinsonisms and loss of sleep paralysis in REM
Fronto-temporal dememtia: Behavioural and semantic decline. In 40-60yrs with FH.

Investigations:
MOCA (26/30 cut-off for cognitive impairment)
Imaging: DAT, SPECT, MRI, CT

Management:
FOR ALL Cognitive enhancers (1st line AChEIs monotherapy e.g. Rivastigmine, galantamine, donepezil. 2nd line Add memantine )
Address BPSD (1st line non-pharma therapies. 2nd line Trazodone for insomnia, Risperidone for psychosis, citalopram for aggression)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Delirium

A

What?
Acute, transient fluctuation in cognition which is reversible. Likely secondary to new illness or medication change
Note: If alongside alcohol withdrawal = Delirium tremens medical emergency

Risk factors:
Vascular - CVA
Infection - UTI, Resp, sepsis etc
Drugs - Diuretics, benzo’s, antihypertensives, anti-cholinergics
Metabolic - Liver encephalopathy, anaemia, DM, cardiac failure, uraemia
Trauma - head injury

Presentation

  • Acute onset
  • Fluctuating consciousness
  • Cognitive impairment (Disorientation, recent memory loss, abstract thinking)
  • Sleep-wake cycle disturbance
  • Visual disturbances
  • Speech disturbance: Incoherent, rapid, slow

Common classification

  • Hyperactive / agitated delirium: Psychomotor agitiation, increased arousal, inappropriate behaviour, psychosis
  • Hypoactive delirium: Psychomotor retardation, lethargy, excess somnolence
  • Mixed delirium: Varied presentation
Management:
-Treat underlying cause
-Optimise environment
- Medication (Avoid sedation e.g. benzo's. Consider regular or PRN haloperidol)
Course:
Average duration of 7 days
30% mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ADHD

A
What?
Attention deficit hyperactivity disorder presenting with
1. Inattention
2. Hyperactivity
3. Impulsiveness

Risk factors:

  • FH
  • Co-morbid illness (ODD, ASD, LD, tic disorder)
  • Maternal smoking or drug use
  • Low birth weight

Assessment:
Rating scale examples Connor’s rating scale and Strengths and Difficulties Questionnaire (SDQ)

Diagnosis Requirement

  1. Onset before <7yrs
  2. Minimum of 6 month symptom history
  3. 2 points of view required
  4. Pervasive across all settings

Management:
Children <5yrs = 1st line ADHD focused group parent training programme. 2nd line Referral to specialist
Children >5 years= 1st line Parent training programme. 2nd line Medication (1. Methylphenidate 2. Lisdexamfetaine 3. Dexamfetamine 3. Atomoxetine or Guanfacine). 3rd line Add on CBT if medication showed benefit.
Adults with ADHD: 1st line medications (1. Lisdexamfetamine or Methylphenidate 2. Dexamfetamine). 2nd line Add-on non-pharmacological Tx.

Monitoring:
	- Height
		○ Every 6 moths in children and young people
	- Weight
		○ At months 3 and 6 after starting medication in children over 10
		○ Every 3 months in Children <10
		○ Every 6 months in adults 
	- CV: BP and HR
	- Tic development
	- Sexual dysfunction
	- Seizures
	- Sleep
	- Worsening behaviour

Prognosis:
By mid twenties….
1/3 will require lifelong treatment
2/3 will no longer require medication that results in an intolerance to medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ASD

A

ASD= Autism Spectrum Disorder

Definition: A group of lifelong developmental disorders characterised by effect on social and communication skills and restricted/repetitive/stereotyped repertoire of interests and activities

Includes:
Autism
Asberger’s syndrome
PDD-NOS

Aetiology:
Unknown
Comorbid conditions: 
- AHDH
- Mood disorders: Depression, BPAD
- Stress disorders: Anxiety, OCD
- LD

Diagnosis requirements:
1. Restricted/repetitive/stereotyped interests and activities
2. Impaired social and communication skills
3. Onset from childhood
4. Impairs everyday function
Also seen: Circadian rhythm dysfunction, mood disorder (anxiety), difficulties in executive function (planning, motivation)

Diagnosis:
By a specialist through detailed history from school and care giver + observation at school/clinic

Primary care management:
-Ensure routine specialist review. Reassessment in secondary care prior to transition to adult services
-Initial management if sleep or behaviour problems present:
§ Evidence of OSA –> Refer
§ Due to mental health or behavioural disorder –> Refer
§ Due to medication (e.g. anti-epileptics or stimulants) –> refer to consultant who initiated them
§ Risperidone can be given short term for aggression
§ Melatonin is 2nd line for sleep disturbance to lifestyle changes.
§ SSRI (e.g. sertraline) for co-morbid anxiety or OCD

Secondary care management:

  • Compose specialised care plan
  • Offer specialist interventions

Prognosis:
Best with early diagnosis, for prompt access to services and support

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Conduct disorders

A

What?
Persistent, repetitive antisocial/aggressive behaviour that violates age appropriate norms

Classification: Conduct disorders and ODD

Onset: Over age 3. If <10 = “early onset”. If >10 = “adolescent onset”

Conduct disorder:
Diagnosis = 6 months history of behaviours, that impacts significantly on schooling and relationships
Who = Boys>, urban population >
Cause = Parents (psychiatric condition, substance misuse), child (low IQ, epilepsy, neuro damage), social disadvantage
Comorbid disease: Neurodevelopmental disorder (ADHD, ASD), anxiety, LD, substance misuse, depression
Complication factors: Substance misuse, neurodevelopmental disorder, LD or mental health problem
Management: If suspected CD then assess presence of complicating factors. If present then specialist referral. If not present then refer to age-appropriate services.
Prognosis: Persistent, esp if in early childhood. Often misdiagnosed as antisocial PD.

ODD:
What? Behavioural disorder characterised by defiant/disobedient/hostile behaviour towards authority figures without violating societal norms.
Who? Boys in childhood years
Outcome? 1/4 show no persistence. Many develop CD or substance misuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Panic disorder

A

Definition:
Recurrence of panic attacks that are no provoked by psychiatric illness, substance misuse or medical condition

Epidiemiolopy:
2.5:1 F:M
Bimodal incidence: 15-20yrs and 45-54yrs

Aetiology:
Highly heritable (evidence that that this increases predisposition, stressors required to trigger onset)

Presentation:

  • Autonomic arousal
  • Hyperventilation syndrome

Management
1st line SSRI
2nd line Change SSRI to SNRI, MAOI, TCA
3rd line Add benzodiazepine (use for 2 weeks during antidepressant induction to cover Sx)
Once medication stabilised disorder, continue for 12-18 months then taper over 2-4 months.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Agoraphobia

A

What?
Panic disorder associated with situation/places with an easy escape, leading to avoidance

Who?
3:1 Females
Bimodal distribution: 15-35 yrs and older

Management
Medical: 1st line antidepressants. Benzos used short term only (e.g. alprazolam)
Psychological: Behavioural methods (Exposure techniques, relaxation training and anxiety management).
Cognitive methods (Teaching about body response to anxiety, education about panic attacks, modification of thinking errors. )

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Generalised anxiety disorder

A

Definition: Characteristic disproportionate, pervasive, widespread and uncontrollable worry with somatic, cognitive and behavioural symptoms

Diagnosis: 6month history on most day of at least 4 of…

  • Autonomic arousal
  • Cognitive Sx
  • Mental state Sx
  • General Sx
  • Tension Sx
  • Physical Sx

Who: Women>, 45-59yr olds

Cause: Triple vulnerability model

Mx: Stepped care approach. If comorbidities present, then assess which is more significant and treat.
Anxiety Symptoms Mild= 1st line period of active monitoring. 2nd line Low intensity psychological intervention. 3rd line: High-intensity psychological intervention OR drug therapy (1. SSRI 2. SNRI 3. Pregabalin)
Anxiety symptoms with functional impairment = 1st line High-intensity psychological intervention OR drug therapy (1. SSRI 2. SNRI 3. Pregabalin)

Referral to specialist services indications
- GAD is complex
- Inadequate response to treatment (high intensity psychological interventions and drug treatments)
- Very marked functional impairment
High risk of self-harm, suicide or self-neglect.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Acute stress disorder

A

What? Reaction to exception stress after 48hr, but before 4 weeks.

Symptoms: More dissociative than acute stress reaction

Management:
1st line Simple practical measures (advice and support)
2nd line Psychological (Bebriefing and CBT)
3rd line pharmacological (TCAs, SSRIs, Benzo’s)

Prognosis:
Either self limiting, or if continued >4 weeks then PTSD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PTSD

A

Definition: Severe psychological disturbance following an extremely traumatic/stressful event

Epidemiology:
Females more at risk
Onset/severity depends on the trauma (rape, torture and prisoners of war have higher risk)

Risk factors:

  • Female
  • Low SES
  • Low education
  • Hispanic/African-american
  • Low self-esteem
  • Psychiatric history

Diagnosis/ Presentation:
From 4 weeks to 6 months of the event, requires all of the following:
- Event occurence
- Re-experiencing (flashbacks or nightmares)
- Avoidance behaviours
-Either: Memory loss around event time OR Hyperarousal symptoms

Management:
If subclinical PTSD –> Watching waiting with regular reveiw
If clinical PTSD, referral to specialist for–>
1st line Psychological (Trauma focused CBT, counselling, EMDR)
2nd line Medical to treat co-morbid symptoms that may be limiting Tx. Not for U18s. See below

Risk management:
If considered high risk (due to severe stress or comorbid depression) –> Referral to crisis resolution of HTT
Care than SNRI and SSRI have slight suicidality risk

Prognosis
2/3 adults symptoms resolve within several months
1/3 symptoms longer lasting, usually enduring and severe

Medical options....
- Anti-depressants  
	○ Venlafaxine or SSRIs e.g. Paroxetine,  Sertraline are licensed for PTSD
	○ Other anti-depressants 
- For sleep disturbances
	○ Mirtazapine, levomepromazine, prazosin
	○ Hypnotics e.g. zopiclone, zolpidem
- For anxiety or hyperarousal
	○ Benzo's e.g. clonazepam
	○ Buspirone
	○ Propranolol
- For intrusive thoughts  / hostility / impulsiveness
	○ Carbamazepine
	○ Valproate, Topiramate
	○ Lithium
- For psychotic symptoms / aggression 
	○ Anti-psychotic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Adjustment disorder

A

Response within 1 month to a psychological stress that persists <6 months after stressor removed.

Classification
- Brief depressive reaction (>1month)
- Prolong depressive reaction (>6 months but <2yrs)
- Mixed anxiety and depressive reaction
- Predominant disturbance of emotions or conduct
(Allows inclusion of grief / bereavement reactions)

Managment
1st line Psychological- Supportive psychotherapy to enhance the capacity to cope with a stressor and establish sufficient support
2nd line Medical - Antidepressants / anxiolytics
Prognosis:
70% resolution in 5 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Depersonalisation / Derealisation syndrome

A

What?
Persistent episodes of distressing feeling of unreality or detachment. Can be in relation to outside world (derealisation) or the person themselves (depersonalisation).
Viewed as a dissociative disorder (DSM-5) or an anxiety/stress-related disorder (ICD-10)

Who?
Rare
Up to 1/2 of normal population may experience depersonalisation, with 1-2% having more chronic symptoms. 
Adolescent/early adulthood onset.
Risk factors:
	- Women> in clinical populations
	- Psychiatric populations

Co-morbidity:

  • Anxiety disorders (OCD, phobias, panic disorder)
  • Depressive disorders
  • Personality disorders (anankastic, obsessional, EUPD)

Differential Diagnosis:
Can be result of..
- Sleep/ sensory deprivation
- Being in unfamiliar surroundings
- Acute stress or trauma
Symptom of..
- Schizophrenia / psychosis (usually with delusional justification)
- Mood / anxiety disorder
- Acute intoxication / alcohol withdrawal
- Substance misused (esp cannabis or hallucinogens)
- Organic disorders

Investigations:
Exclude organic cause, can include brain imaging and EEG

Management:
Rating e.g. The Cambridge Depersonalisation Scale.
Approach
- Exclude organic cause
- Identify and treat psychiatric condition if present
- No licenced drugs un UK.
○ SSRIs have some evidence (escitalopram or citalopram) alone in combo with lamotrigine
- Psychological intervention
○ CBT has shown benefit.

Course:
Sudden onset, with gradual resolution.
Chronic symptoms run a fluctuating course, and may be treatment resistant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

OCD

A

Definition: Characterised by obsession and delusions that cause distress and functional impairment. Thoughts are seen as own and patient has insight. Obsessions are intrusive, repetitive and distressing thoughts/images recognised as one’s own. Compulsions are stereotyped and purposeless actions performed to reduce anxiety of obsession

Who?
F:M
Typical onset at age 20

Aetiology:
GAS association

Presentation:
Clusters of symptoms: Pre-occupation with hygiene, worry about safety, abhorrent thoughts/impulsesab
Symptoms: Contamination, checking, aggressive/violent thoughts, washing, symmetry, counting

DDx

  • Anankastic PD
  • Depressive disorder
  • Bodily dysmorphic disorder
  • Anxiety
  • Alcohol and substance misuse
Diagnostic criteria: 3/3 required
1. Obsessions
2. Compulsions
3.Anxiety or functional impairment
(No time frame)

Management:
Adults with MILD impairment = Low intensity CRT + ERP
Adults with MODERATE impairment = High intensity CRT + ERP OR SSRI (2nd line TCA e.g. clomipramine)
Adults with SEVERE impairment / at risk / comorbid illness = Refer for specialist assessment and treatment. Consider Moderate Mx whilst waiting.

Child with MILD impairment = 1st line Refer for self-help therapy. No improvement? Refer to CAMHS
Child with MODERATE-SEVERE impairment = CAMHS referral

Note: SSRI initial dose higher in OCD so expect initial response after 12 weeks. Caution of increased suicidality risk so arrange follow-up after 1 week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Somatisation Disorder

A

What?
Disorder where there is repeated presentation with medically unexplained symptoms, affecting multiple organ systems.
First presenting before the age of 40yrs.

Who?
Adults = Usually chronic
Children = Impacts 1-3 organ systems for a shorter period of time

Associations
Psychological distress
Functional impairment
Risk of iatrogenic harm

Management

- Make, document, and communicate the diagnosis. 
- Acknowledge symptom severity and experience of distress as real, but emphasize negative investigations and lack of structural abnormality. 
- Reassure the patient of continuing care.
- Attempt to reframe symptoms as emotional. 
- Assess for, and treat, psychiatric comorbidity as appropriate. 
- Reduce and stop unnecessary drugs. 
- Consider a case conference involving the GP and treating physicians. Educate the parents/family.
- For children and adolescents: Rehabilitation and return to usual activities. 

Prognosis
Poor in the full disorder, tendency is for chronic morbidity, with periods of relative remission.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Personality disorders

A

Definition: Inflexible, enduring and disruptive behaviour patterns that cause distress or impaired function. Tends to impair functions in affect, behaviour and cognition. Sufferer can have insight but not necessary for Dx.

Risk factors:

  • FH: Relative of schizophrenic. Can develop into overt schizophrenia
  • 4% population
  • Female prisoners 7%
  • Poor upbringing

Classifications:
Paranoid= Sensitive/suspicious
Schizoid = Emotionally cold, detached, disinterested in other
Schizotypical with schizophrenia = Interpersonal discomfort with peculiar ideas etc
EUPD (Types: impulsive / borderline) = Emotional instability managed with outbursts of rage or self-destructive behaviour
Histrionic = Dramatisation, attention-seeking, risk taking behaviour, manipulative
Narcissistic = Lack of empathy, need for admiration
Dissocial = Callous, lack of concernfor others. Unable to maintain relationships.
Anxious = Tension, self-consciousness, fear of criticism
Dependent = Clinging / submissive. Feels helpless without partner
OCD
Anankastic = Preoccupation with control, perfectionism, rigidity, doubt/indecisiveness

Clusters:
A (Weird) e.g. Paranoid, schizoid, schizotypical
B (Wild) e.g. Narcisistic, EUPD, Dissocial, histrionic
C (Worried) e.g. Anankastic, Anxious, OCD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Psychopathy

A

Presentation:
EMOTIONAL FEATURES
- Interpersonal e.g. Glibness, manipulative, grandiose sense of self-worth, lying
- Affective e.g. Failed responsibility, callous, lack of guilt, shallow effect
-Romantic e.g. promiscuous sexual behaviour, short martial history

BEHAVIOURAL FEATURES

  • Lifestyle e.g. irresponsibly, impulsive, needs stimulation, lack of long term goals
  • Antisocial e.g. poor behavioural control

Diagnosis:
Scoring on the PCL-R (psychopathy classification- revised)
Requires a score >25/40
Requires features of emotional AND behavioural nature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Puerperal disorders

A

3 classification: Baby blues, post-partrum depression, post-partrum psychosis, pre-existing psychiatric illness

BABY BLUES
3/4 women get it
Occurs 3-4 days after delivery, for 1-2 days
Px: Irritability, labile mood, tearfullness
Mx: Reassure and observe until resolution

POSTPARTUM DEPRESSION
Who: 1-2% women
Risk factors: Depression history, eating disorder history, FH, single mother, unwanted pregnancy, baby blues
Occurs: Peak 3-4 weeks after delivery, within 6 months of birth
Features: Symptoms of depression
Management: Early detection and Risk assess with EPDS. Always ask about self-harm and harm to baby. Mild - CBT. Moderate - SSRI. Severe= Consider admission

POSTPARTUM PSYCHOSIS
What? Acute psychosis after delivery
Who? 1.5/1000 births. 30% recurrence
Risk factor: Previous of postpartum psychosis, FH of psychosis, Single parenthood, little social support
Presentation: 80% affective symptoms, 15% Schizophreniform
Management: Consider admission to psychiatric mother and baby unit. If Major affective disorder: ECT, mood stabilisers (esp carbamazepine) and early antidepressant use.

CHILDBEARING IN PATIENTS WITH PRE-EXISTING MENTAL DISORDERS
Schizophrenia: Patients are less likely to relapse post-partum if they stay on treatment.
Bipolar: 2/3 will relapse post-partum. Increased risk is FH of post-partum psychosis, 4+ illness episodes pre-pregnancy or medications discontinuation mid-pregnancy
Eating disorders: Risk of postnatal depression and poorer health outcomes for baby.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Alcohol misuse

A

Alcohol physiology:
GABA-A agonist —> Anxiolytic
NMDA antagonist –> Amnesia
Dopamine agonist –> Euphoric

Assessment:
Alcohol-related problems: CAGE questionarires
Alcohol dependence: SADQ
Alcohol withdrawal: CIWA-Ar

Presentation:
Alcohol abstinence
Alcohol withdrawal
Alcohol withdrawal seizures
Delrium Tremens
Korsakoffs syndrome (if severe with Wernicke's encephalopathy --> Wernicke-korsakoff syndrome. Wernicke's presents with Ataxia, confabulation and visual problems)

Investigations:
BAC
Bloods (elevated MCV, G-GT, CDT sign of excessive consumption)
Urinary alcohol level (remains elevated for days)

Management:

  • Acute withdrawal = Alcohol reducing regime
  • Alcohol withdrawal seizures = Consider lorazepam
  • DT = Oral lorazepam
  • Wernicke’s encephalopathy= Pabrinex 2 x vials TDS for 3 days

Maintaining abstinence treatment options

  1. Disulfram “Antabuse”
  2. Acamprosate (NMDA antagonist that reduces cravings)
  3. Naltrexone (Opioid receptor antagonist that reduces Dopamine release to reduce pleasure of alcohol consumption

Alcohol reducing regime:
Using? Diazepam if inpatient. Chlordiazepoxide if outpatient.
Duration: 5-7 days
Indications: >10 units in last 10 days, Hx of dependence, withdrawal symptoms

Complications:

19
Q

Delirium Tremens

A

Definition: Acute confusional state associated with alcohol withdrawal. Occurs 1-7 days after cessation and peaks after 48hrs.
Risk: 10-15% mortality
Management: 1st line Oral lorazepam. 2nd line parenteral Lorazepam or haloperidol

20
Q

Substance misuse: Depressants

A

Depressants
o Drugs: Benzodiazepines, barbiturates, alcohol, Chlordiazepoxide, pregabalin, gabapentin
o BZDs
○ MoA: GABA agonist
○ Effect: Anxiolysis and euphoria
○ Tolerance: Develops quickly
○ Dependency: Develops after 3-6 weeks of regular use
○ Withdrawal: Complicated by seizures and delirium
○ Side effects:
§ Acute: Forgetful, drowsy, impaired concentration + co-ordination
§ Chronic: Impaired concentration, memory and depressed mood
○ Risk:
Limb ischaemia if IV route of melted tablet use

21
Q

Substance misuse: Stimulations

A

Stimulants
o Drugs: Amphetamines, cocaine, MDMA, caffeine
o MoA: Prevents NMDA reuptake
o Effect: Increased alertness and endurance, insomnia and subjective sense of well-being
o Risk: In overdose can cause cardiac and cerebrovascular problems
o Dependence: No physical dependence symptoms
Withdrawal: Rebound lowering in mood and intense craving

22
Q

Substance misuse: Hallucinogens

A

o Drugs: LSD, mescaline, psilocybin, PCP, Ketamine
o Psychoses common
Risk: Prolonged heavy use links to schizophrenia

23
Q

Substance misuse: Opiates

A

Opiates
- Drugs: Morphine, heroin, methadone, buprenorphine, dihydrocodeine, fentanyl, pethidine
- MoA: Agonist of delta, kappa and mau receptors.
- Manifestations: Physical dependence, tolerance and withdrawal syndrome.
o IV opioids withdrawal: Craving, rhinorrhoea, lacrimation, vomiting etc. Examination reveals tachycardia, hypertension, mydriasis and facial flushing
-Withdrawal: COWS (Clinical Opioid Withdrawal Scale)
-Risk: Respiratory depression in overdose
- Opiate overdose
o Signs: Pinpoint pupils, unrousable, pale skin, blue lips, shallow / slow breathing, snoring /rasping breaths
oNaloxone is an inverse opiate agonist that is can be given in emergencies. IM injection given in 0.4ml doses. Brand name is Prenoxad (contains Naloxone hydrochloride). Wait 2-3 mins for response before next dose.

24
Q

Substance misuse: Cannabinoids

A

Cannabinoids
- Drugs: Cannabis
- Psychoactive component: Tetrahydrocannabinol (THC)
- Effects
o Immediate: Mild euphoria (“the giggles”), a sense of enhanced well-being, enhanced subjective sensation, relaxation, altered time sense and increased appetite
o Physically: Mild tachycardia, variable dysarthria and ataxia
o Harmful acute affects: Paranoia, panic attacks and delayed reaction time induced accidents
o Harmful chronic effects: Dysthymia, anxiety/depression, amotivational syndrome
- Duration: Immediate effect after smoking, lasting 2-5hrs.
- Testing: Urine sample contains positive for up to 4 weeks after regular use due to metabolite distribution in to fat.
- No physical dependency
Mild withdrawal for chronic users e.g. irritability, insomnia and anxiety

25
Q

Opioid management

A
DETOX
Symptom management: 
- Lofexidine for autonomic symptoms
- Loperamide for diarrhoea
- NSAIDS for myalgia
-Metoclopramide for N/V

Substitute prescribing:
- Oral Methodone OR SL buprenorphine

Relapse prevention:

  • Methadone for maintenance (Dose dependent on the withdrawal symptoms after 24hrs cessation. Max dose at initiation if 30mg. Dose reduction over 4-6 months)
  • Naltrexone used to reduce addiction (it’s an opiate antagonist so block euphoria)
OVERDOSE
IM naloxone (opiate antagonist). Given in dose of 0.4ml, repeated after 2-3 mins  if required.
26
Q

Benzodiazepine withdrawal

A

Substitute prescribing: Convert dose to Diazepam (long-acting) to avoid withdrawal symptoms. Taken BD. No long-term maintenance programme. Dose reduction key to avoid chronic harm

27
Q

Depression

A

Defintion:
Persistent low mood and anhedonia that has marked social impairment on functioning

Epidemiology:
5% of the general population
10-20% chronically-ill patients leading to worse outcomes

Age?
>20s
Elderly

Symptoms:
Core: Anhedonia and low mood
Typical: Fatigue, Weight loss, insomnia, guilt/worthlessness, trouble concentrating, agitation, suicidal/DSH thoughts
Atypical: Weight gain, hypersomnolesence, reactive mood, sensitivity to rejection

DDx:

  • Dysthymnia
  • Subthreshold depressive disorder
  • Seasonal affective disorder

Diagnosis: Presence of >5 core symptoms for at least 2 weeks of sufficient severity to cause clinically significant distress or impairment in social/occupational functioning.

Diagnosis classification  (DSM 5 - Used by NICE)
Mild = 5 core/typical symptoms with manageable distress, minor social/occupational impairment
Moderate = 5 core/typical with variable social/occupational impairment
Severe = 5 core/typical symptoms with manageable distress and significant social/occupational impairment

Management:
Mild-moderate = Low intensity psychological therapy e.g. individual guided self-help, CBT or structured group-based physical activity programme
Severe = High intensity psychological therapy and anti-depressant (1st line SSRI e.g. Fluoxetine, sertraline, citalopram, paroxetine)

Where medication is indicated:

1. Give SSRI and monitor for 4-6 weeks (expect some response after 2-3. Max response at 6). Continue for at least 6 months following remission of symptoms 
- No signs of improvement? Consider dose increase or switching SSRI. 
2. If still no improvement… Switch to different class e.g. venlafaxine, mirtazapine
3. If partial or no improvement consider specialist referral

Prognosis:
50% of those with one episode will have another, 90% who’ve had 3+ will recur
Risk of suicide is 10x greater following a single episode.

28
Q

Deliberate self-harm (DSH)

A

Risk factors for DSH:

- History of abuse or trauma
- Girls or young women
- Looked after and accommodated
- Social groups: LGBT, Asian women
- Exposure to someone who self-harms
- Youth subcultures (e.g. Goths)

Those are risk of suicide:

- Previous self-harm
- Suicide in close relatives/friends
- History of abuse, neglect, bullying
- Loss events (bereavement, employment)
- Low SES, forensic history
- Substance misuse
- Access to lethal means

Suicide demographics:

  • Male
  • FH
  • Occupation: Farmer, Dr
  • Family: Childless, single
  • Age: Older

In young people, when to refer to CAMHS:
Indicated?
-Suspected mental illness
-Young people at risk of suicide or serious self-harm
-Complexity
Not indicated?
-No mental illness
-Impulsive self-harm / situation resolved
-(Use clinical judgement or discuss with CAMHS if unsure)

29
Q

BPAD

A

Definition: Bipolar Affective disorder characterised by 2+ episodes in which there has been mania/hypomania AND depressed mood. History of hypomania/mania only is “Bipolar disorder)

Classification:
Type I: 1 x mania/hypomania AND 1x depressive ep
Type II: Where the depressive episodes are more prominent and severe, but still history of hypomania/mania

Epidemiology:
1-2% lifetime risk
F:M
Precipitating factors = Childbirth, ECT

Aetiology:
Genetic> environmental influence

Differentials:
Affective disorder= Mood congruent psychosis with mood disorder
Schizoaffective disorder= Bipolar + schizophrenia (hallucinations, delusions, lost insight)

Management:
All first presentations to primary care should be referred to specialist. Only taper antidepressant or initiate anti-psychotic under specialist advice.
In secondary care…
ACUTE MANIA or HYPOMANIA: Immediately taper anti-depressant and consider short term Benzo. Commence antipsychotic (1st line Risperidone/ Quetiapine / Olanzapine. 2nd line trail different anti-psychotic. 3rd line Lithium or NaVal, takes longer to have effect).
ACUTE DEPRESSION IN BPAD: Immediately start anti-psychotic (1st line Fluoxetine + olanzapine / olanzapine lamotrigine). If severe-moderate depression then co-prescribe antidepressant, but discontinue after 8 weeks of depression remission
MAINTENANCE 4 WEEKS AFTER ACUTE EPISODE: Minimum treatment duration for all is 2 years. Not all stay on meds forever. Indication for maintenance prophylaxis (1 mania ep with severe risk, repeated hypomania or depressive ep with risk)

Monitoring:
3 monthly: Lithium levels
6months: Bloods (Ca, TFTs, U+Es), BP, ECG and BMI.

Co-morbidities:

  • CDV
  • DM
  • COPD

Prognosis:
90% recurrence after first episode
10-15% completed suicide
“Rapid cycling” is there are 4+ episodes in a year, suggests poor prognosis
Average patients have 4 episodes every 10 years

30
Q

Schizophrenia

A

Definition: Characterised by delusions of passivity and thought disorder, hallucinations (typically auditory) with lack of insight.

Differential Diagnosis:

  • Schizoaffective disorder
  • Delusional disorder (3+ month history of delusions only)
Epidemiology
1% of population
Presents in 20s -mid-30s 
1/5 will only have a single episode 
Men > (women present later)
10% suicide risk
Reduced lifespan by 15 years

Aetiology
Developmental: Childbirth trauma or early abuse
NT: Elevation of dopamine mesolimbic pathway
Drugs: Prolonged cannabis use

Presentation: ICD 10
The following should be present most of the time for >1 month

1+ of:
- Thought disorder
-Delusions of control or passivity
- Bizarre delusions
- Hallucinations (2nd person auditory)
OR
2+ of:
- Other hallucinations occurring daily or associated with fleeting delusions or sustained overvalued iseas
- Thought disorganisation (loosening of associations, incoherence, neologisms)
-Catatonic symptoms
-Negative symptoms
-Change in behaviour

Scheider’s first rank symptoms:

  • Delusional perception
  • Thought disorder
  • Delusions of control
  • Hallucinations: Audible thoughts (1st person or thought echo), 2nd person commentary

Classification:

  • Paranoid (Positive symptoms (delusions and hallucinations> negative and thought disorder, later onset with better prognosis)
  • Hebephrenic (Thought disorganisation, disturbed behaviour and altered affect. Earlier onset with poorer prognosis)
Management:
ANTI-PSYCHOTICS
Aim= Reduce positive symptoms, no effect on negative Sx (apathy, social withdrawal)
Duration=1-2 years after first episode. Reduce over a few weeks to reduce relapse. Most people on lifelong tx
Side effects: Commonly somnolence, weight gain, EPSEs. Photosensitivity in chlorpromazine, GTc prolongation in haloperidol. Agranulocytosis and hypersalivation in clozapine
BENZODIAZEPINE
Use lorazepam short term
PHYSICAL HEALTH MONITORING
-Annual health screen, with CVD focus
-ECG prior to commencing anti-psychoitcs
PSYCHOLOGICAL TREATMENTS
CBT proven to be effective
Prognosis

Treatment resistant schizophrenia:

  • Definition? 2+ failed anti-psychotics used for 6+ months each
  • Options: 1st line Clozapine.
31
Q

Intellectual disability

A

Definition: Childhood onset of low IQ (<70) with impaired social and adaptive function

DDx:

  • Learning disability (doesn’t always have a reduced IQ)
  • Dementia (here there is loss of pre-existing cognitive function)

Epidemiology
1-2% of the population
3M:2F
85% of those diagnosed will have “mild” form

Associations:
1/3 will have co-morbid psychiatric condition

Aetiology:
Genetics: Chromosomal (Down’s, fragile X, Prader-Willi), Tay-sachs, PKU, tuberous sclerosis
Prenatal: TORCH infection, syphilis, substance misuse (Foetal abstinence syndrome), Complications (IUGR, pre-eclampsia)
Perinatal: Prematurity, birth trauma
Environmental: Neglect and lack of stimulation
Neuropsychiatric: ASD, ADHD, Rett’s syndrome
Childhood medical condition: Infection (e.g. meningitis, encephalitis, measles) Toxins, Head trauma

Classification:
Mild (IQ 50-69)
Moderate (IQ 35-49)
Severe (IQ 20-34)
Profound (IQ <20)

Management:
If suspected in primary care –> Refer to local LD service team. Consider referral to clinical psychologist, mental health services and genetics if indicated
In confirmed LD –> 1st line MDT care + annual health check

Indications to admit:

  • Respite for caregivers
  • Require inpatient care due to: Complex LD, severe behavioural problems, physical impairment
  • Complex resistant psychiatric disorder
  • Requires assessment
32
Q

Serotonin Syndrome

A

Definition: Manifestation of concomitant use of 2+ highly serotinergic drugs

Drugs:
Anti-depressants e.g. MAOIs, SNRIs and SSRIs
Stimulants e.g. Ecstasy, amphetamines

Differential Diagnosis: Neuroleptic malignancy syndrome

Signs and symptoms
"Shits and shiver"
Shits
Shivers
Hyperreflexia
Increased temperature
Vital signs (increase HR and BP)
Encephalopathy
Restlessness and tremor
Sweats

Management:
1st line ABCDE. Withhold seritonergic drug. Supportive care (IV fluids, cooling). Give benzodiazepines
2nd line Serotonin antagonists e.g. cyproheptadine or chlorpromazine
3rd line ICU (ventilation and intubation)

33
Q

Anorexia Nervosa

A

Definition: Disordered eating due to fixed and pervasive fear of fatness than leads to low weight.

Associations:
Binging, purging, laxative/diuretic use and excessive exercise.

Epidemiology:
Females
Adolescent presentation

Risk assessment:
BMI <17.5
Vitals: Low HR, Low BP
Bloods: Low Na, Low K, elevated transaminases, elevated U+Es, hypoglycaemia,
ECG: Bradycardia, QTc, pathological t waves (low K)
SUSS test

Diagnosis requirements:

  • Irrational fear of weight gain
  • Low BMI (<17.5 or recent severe drop in weight)
  • Restriction energy intake
  • Overvalued importance of weight for self-evaluation

Referral from Primary care:

  • ALL with suspected eating disorder (BMI <17.5 or rapid weight loss)
  • urgent is BMI <15

Admission considerations:

  • Risk of refeeding syndrome
  • Acute mental health risk
  • Lack of home support

Refeeding

  • Give all adults thiamine and Pabrinex
  • Assess the risk of refeeding syndrome (low electrolytes, low BMI and co-morbid health concerns e.g. infection, DM)
  • If risk of refeeding syndrome present, give slower initial feeding dose with BD electrolyte monitoring
  • If low risk, give 15-20kcal/kg/day
  • Monitoring:BMI, Na,K ,Ph, Vital signs and ECG

Management:
Adult 1st line: CBT-ED
Child 1st line: FT-AN

Prognosis:
30-40% fully recover by 9 years time
20% develop chronic intractable disease
Long term mortality rate of 10-20% due to complication / suicide

Complications:
CVS= Arrhythmia, QTc prolongation, hypotension
GI: Constipation, refeeding pancreatitis, hepatitis
Haematological: Pancytopaenia, decreased ESR
Pulmonary: Resp failure, spontaneous pneumothorax
Metabolic/endocrine: Amenorhoea, hypoglycaemia, osteoporosis, infertility, hypercorsitolaemia, decreased thyroid function

34
Q

Bulimia nervosa

A

Definition: Disorder eating with habits of purging and bingeing, that typically results in normal weight.

Epidemiology:
-Later then AN

Presentation:

  • Pitted teeth
  • Normal BMI
  • “Russels sign” of calluses on knuckles
  • Parotid gland enlargement

DDx: Binge eating disorder

Management:
At primary care –> Referral ALL to specialist secondary care
In secondary care
1st line: Adults (BN-focused self help for 4 weeks) children (BN-focused family therapy)
2nd line: CBT-ED
Pharmacology options: High dose fluoxetine for 1 year.

Complications to purging
GI
	• Dental  erosion
	• Parotid gland swelling
	• Oesophageal rupture
	• GI reflux
	• Barrett's oesophagus
	• Constipation due to laxatives
	• Cathartic colon
	• Mallory-Weiss tear
Pulmonary
	• Aspiration
Cardiac
	• Arrhythmias
Metabolic
	• Hypokalaemia
	• Dehydration
	• Metabolic acidosis (Due to laxative abuse)

Prognosis:

  • Lower mortality vs AN
  • 10years on 10% unwell with BN and 20% have subclinical BN
35
Q

Lithium Toxicity

A

Monitoring: Every 3 months.

Levels:

  • “Safe” up to 1.2
  • Toxic levels >1.5

Symptoms:
GI = Diarrhoea (blood or watery), N/V, anorexia
Renal = Polydipsia / polyuria –> Acute tubular necrosis
CNS = Myoclonic jerks, fasciculations, Course tremor –> Drowsiness –> Coma
CVS= Hypotension, brugada syndrome, dysrhythmias –> Circulatory collapse

36
Q

Risk of methylphenidate

A

Cardiomyopathy, HTN and appetite suppression

37
Q

Risk of SNRI

A

Venlafaxine: HTN
Mirtazepine : Weight gain and sedation

Slight high overdose risk than SSRIs.
Withdrawal risk due to short half-life

38
Q

Anti-psychotic

A

Typicals (Dop selective): Haloperidol, Chlorpromazine, Zuclopentixol, Sulpride
Atypicals (broad spectrum): Risperidone, olanzapine, quetiapine, amisulpride, clozapine

Side effects:
Atypicals: Metabolic syndrome, GI updset, QTc prolongation, sedation
Atypicals: EPSEs (AdAPT) and hyperprolactinaemia
Clozapine: Agranulocytosis, paralytic ileus, metabolic syndrome, cardiomyopathy, reduced seizure threshold

MONITORING
Baseline: FBC, U+Es, LFTs,, Lipids, weight, BM, prolactin, BP, ECG
At 3 months: Lipids and weight
At 6 months: BM, prolactin
Annually: CVS risk assessment, BM, prolactin, Lipids and weight, FBC, U=Es and LFTs

39
Q

Clozapine

A

Use
- Specifically for treatment resistant schizophrenia (i.e. Failure of 2+ antipsychotics for 6-8 weeks)

Benefits
- Less EPSEs

Side effects

- -> Marrow toxicity --> Neuropenia, Agranulocytosis 
- -> Intestinal paralysis --> Faecal compaction, intestinal obstruction and paralytic ileus 
- -> Weight gain --> Metabolic syndrome
- -> Myocarditis / cardiomyopathy 
- ->Reduced seizure threshold
Contraindications
	- Alcohol and toxic psychoses
	- Bone-marrow disorders
	- Coma
	- Drug intoxications
	- History of:
		○ Agranulocytosis
		○ Circulatory collapse
		○ Neutropenia
		○ Ileus
	- Uncontrolled epilepsy 

Caution

- Over 60s
- Prostatic hypertrophy
- Susceptibility  to  angle-closure  glaucoma
- Taper of other  antipsychotics before  starting

Monitoring

- Baseline ECG taken prior to treatment commencement
- Weekly blood for first 18 weeks, then monitoring becomes less frequent
- Dose adjustment if smoking starting during treatment (CY P450 induction, which enhances metabolism of some drugs. Smoking = Less drug in circulation)
40
Q

Benzo withdrawal

A

Delayed by 5-7 days after sudden cessation

Features:

- Typical withdrawal symptoms e.g. n/v, anorexia, agitation, fits, insomnia, tremor
- Characterised by perceptual distortions e.g. distorted visual relationships, walking on cotton wool (suggests temporal lobe focus)
41
Q

ECT

A

Indications: Depression, establish mania, schizophrenia (only certain types), puerperal psychosis

Side effects: Amnesia common. Headaches, confusion, nausea, muscle pain.

Relative contraindications:

  • Heart disease
  • Increased ICP
  • Risk of cerebral bleeding
  • Poor anaesthetic risk

Response:
50% response rate
Benefits wear off after 2-6 weeks so require follow-up anti-depressants after.

42
Q

Requirements for detainment

A

Act exclusions

- Sexual acts
- Behaviour that isn't in alignment with how a prudent person would behave

Criteria for detainment (all required)

- Impaired capacity
- Suspected or diagnosed mental disorder 
- Risk to self or others
- Necessary to determine or undergo treatment
- Cannot be given informally 
- Medical treatment is available
43
Q

Timing of alcohol…
Withdrawal
Seizures
DT

A

Symptoms of WITHDRAWAL start at 6-12 hours: tremor, sweating, tachycardia, anxiety

Peak incidence of SEIZURES at 36 hours

Peak incidence of DELIRIUM TREMENS is at 48-72 hours: coarse tremor, confusion, delusions, auditory and visual hallucinations, fever, tachycardia